Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04979338 · ClinicalTrials.gov registry record · Phase 3

Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries

A Phase 3 study of Gender Dysphoria, sponsored by Cedars-Sinai Medical Center.

Recruiting
Registry status
Phase 3
Development phase
640
Enrollment target
1
Study location

NCT04979338 is a Phase 3 study of Gender Dysphoria that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 640 participants, above the 99-participant average among 8 other Gender Dysphoria trials with a reported enrollment target (546% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04979338, a Phase 3 study of Gender Dysphoria, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.

RECRUITING
Registry status
Phase 3
Development phase
640 participants
Enrollment target
1
Study location

Study Summary

This study will compare the current standard-of-care pain treatment regimen options that are available to patients who undergo gender-affirming surgery. The purpose of this research is to determine if any of these options are more (versus less) effective than the others to manage surgery related pain, after surgery.

Conditions Studied

Interventions

  • DRUG Bupivacaine
  • OTHER Ultrasound guided Continuous Infraclavicular Brachial Plexus Block
  • OTHER Ultrasound guided Continuous Femoral Nerve Block
  • OTHER Ultrasound guided Pudendal Nerve Block
  • OTHER Bilateral ultrasound guided Transversus Abdominis Plane Block

Study Locations (1)

California

  • Cedars-Sinai Medical Center - North and South Towers - Los Angeles

Trial Details

FieldValue
Enrollment Target 640 participants
Start Date 2021-11-11
Est. Completion 2026-09-30
Phase Phase 3

Sponsor

Cedars-Sinai Medical Center

339 total trials

What the Registry Record Tells You About NCT04979338

The ClinicalTrials.gov registry entry for NCT04979338 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 8 other Gender Dysphoria trials with a reported enrollment target (546% higher). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gender Dysphoria appearing as the primary indexed condition, and to 5 interventions - of which Bupivacaine is the first listed.

NCT04979338 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04979338 about?

NCT04979338 is a clinical study titled "Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries". This study will compare the current standard-of-care pain treatment regimen options that are available to patients who undergo gender-affirming surgery. The purpose of this research is to determine if any of these options are more (versus less) effective than the others to manage surgery related pai...

What is the current status of trial NCT04979338?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 640 participants. The study started on 2021-11-11. Estimated completion is 2026-09-30.

What conditions does trial NCT04979338 study?

This clinical trial studies the following conditions: Gender Dysphoria.

What interventions are being tested in trial NCT04979338?

The interventions under investigation include: Bupivacaine (DRUG), Ultrasound guided Continuous Infraclavicular Brachial Plexus Block (OTHER), Ultrasound guided Continuous Femoral Nerve Block (OTHER), Ultrasound guided Pudendal Nerve Block (OTHER), Bilateral ultrasound guided Transversus Abdominis Plane Block (OTHER).

Who is sponsoring clinical trial NCT04979338?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04979338 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gender Dysphoria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.